New eye ointment aimed at soothing chronic eyelid inflammation

NCT ID NCT06400511

Terminated Disease control Sponsor: Famy Life Sciences, a Viatris Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a medicated ointment called pimecrolimus 0.3% for people with blepharitis, a condition that causes red, irritated eyelids. The trial planned to include 477 participants aged 2 and older, applying the ointment twice daily to the eyelid margins. The main goal was to see if it could clear eyelid debris and reduce discomfort. However, the study was terminated early, so final results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pimecrolimus 0.3% ophthalmic ointment
What this could lead to: If successful, this could provide a new treatment option for blepharitis, reducing eyelid debris and discomfort.
What could go wrong: The study was terminated, so results are incomplete. It is unclear if the ointment works better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blepharitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEPHARITIS

Contacts and locations

Locations

Clinical Investigative Site

Pheonix, Arizona, 85032, United States
Clinical Investigator Site

Garden Grove, California, 92843, United States
Clinical Investigator Site

Glendale, California, 91204, United States
Clinical Investigator Site

Inglewood, California, 90301, United States
Clinical Investigator Site

Newport Beach, California, 92663, United States
Clinical Investigator Site

Petaluma, California, 94954, United States
Clinical Investigator Site

Rancho Cordova, California, 95670, United States
Clinical Investigator Site

Aurora, Colorado, 80045, United States
Clinical Investigator Site

Crystal River, Florida, 34429, United States
Clinical Investigator Site

Largo, Florida, 33773, United States
Clinical Investigator Site

Tampa, Florida, 33603, United States
Clinical Investigator Site

Atlanta, Georgia, 30339, United States
Clinical Investigator Site

Morrow, Georgia, 30260, United States
Clinical Investigator Site

Pittsburg, Kansas, 66762, United States
Clinical Investigator Site

Louisville, Kentucky, 40206, United States
Clinical Investigator Site

Havre de Grace, Maryland, 21078, United States
Clinical Investigator Site

Medina, Minnesota, 55340, United States
Clinical Investigator Site

Kansas City, Missouri, 64154, United States
Clinical Investigator Site

Washington, Missouri, 63090, United States
Clinical Investigator Site

Garner, North Carolina, 27529, United States
Clinical Investigator Site

Cincinnati, Ohio, 45242, United States
Clinical Investigator Site

Cranberry Township, Pennsylvania, 16066, United States
Clinical Investigator Site

Smyrna, Tennessee, 37167, United States
Clinical Investigator Site

Austin, Texas, 78731, United States
Clinical Investigator Site

Lakeway, Texas, 78738, United States
Clinical Investigator Site

San Antonio, Texas, 78229, United States
Clinical Investigator Site

Clinton, Utah, 84015, United States
Clinical Investigator Site

Lynchburg, Virginia, 24502, United States
Investigative Site

St Louis, Missouri, 63131, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.